Ecovamed offers an innovative Life Cycle Assessment (LCA) solution to evaluate and reduce the carbon footprint of medicines, medical devices, pharmaceutical ingredients, and more generally the carbon footprint of (bio)chemicals, natural products and materials. Multi-impact LCAs with up to 16 environmental impacts are also routinely performed.
Ecovamed is also supporting health professionals in their healthcare eco-design efforts, and developped recently an application to compare the carbon footprints of single-use medical devices and reusable devices, with steam sterilization. You can test it now, it's free!
Our ambition is to contribute to a sustainable access to health products, such as medicines and medical devices, while promoting manufacturing processes with lower environmental impact, by democratizing carbon footprints and Life Cycle Assessment within the medical, pharmaceutical and chemical industries.
Ecovamed technology is based on an innovative methodology, coupled with databases that have been specifically designed to assess or validate the manufacturing process and geographical origin of drug substance manufacturing across the whole supply chain. This unique technology has been enriched to allow the evaluation of the carbon footprint of medicines, medical devices, chemicals, materials and biologics, from data easily available to manufacturers and at a very attractive cost due to the process automation.
Ecovamed is a technology-oriented company, taking part of the best of data analysis and algorithms, while keeping a strong human component when it comes to the analysis and interpretation of the results.
Integrity
Promote sincere, honest and scientifically-validated information
Innovation
Create new technologies that will make these services affordable to all stakeholders
Impact
Tackle sustainability challenges
for health and chemical products
Ecovamed offers competitive and easy-to-use services to perform Life Cycle Assessement (LCA) or Carbon Footprint evaluation of your products, and also Corporate and Site Carbon Accounting
You need the carbon footprint or the Life Cycle Assessment (LCA) of a (bio)chemical you manufacture or you buy? Or you need it for a medicine or a medical devices?
Ecovamed proposes tailor-made carbon footprints complying with the GHG Protocol standard, at a very competitive price, and also multi-impact LCA conforming with the ISO 14040-14044.
Ecovamed specializes in the LCA and carbon footprints of active ingredients, their intermediates and more generally (bio)chemicals and natural products, which are the key drivers for medicines LCA. This focus has enabled the development of an innovative solution to significantly reduce the cost of these footprints, to make them accessible to all stakeholders, and increasing at the same time the quality of results.
The objective is to reduce the environmental impact of end-users and also to facilitate scope 3 calculation and reduction, in creating new purchasing criteria based on the environmental footprint of your suppliers.
You want to reduce the greenhouse gas emissions of your company and set up a climate roadmap?
Ecovamed performs corporate carbon accounting according to the GHG Protocol standard and also complying with the French BEGES regulation.
The key strength of Ecovamed sits in a rigorous scope 3 evaluation, with in-depth analysis of categories which are often approximated, such as "purchasing of goods and services", waste treatment and capital goods. We also offer solutions to work with your supply-chain to reduce your scope 3 emissions.
Ecovamed developped the first database with all oral medicine carbon footprints. Injectable and other medicines will come soon. This database will be opened as soon as the submitted scientific publication will be publised, to give full transparency on the methodology.
Create my accountThe objective of Ecovamed is to give free access to all medicine carbon footprints to hospital medical doctors and pharmacists engaged in healthcare pathways eco-design.
For private companies, an annual subscription fee will be communicated mid 2024, at the opening of the database.
In a first step, the database will give the carbon footprint of all oral medicines of the French pharmacopoeia, with the assessed uncertainty and a breakdown of the 3 main categories (raw materials, manifacturing and distribution).
In a second step, the full French pharmacopoeia will be available.
If you are interested in sub-categories, such as the Active Pharmaceutical Ingredient carbon footprint, feel free to contact us for tailor made requests!
Recycling PVC-based medical device cuts greenhouse gas emissions by 25% compared to incineration
Hospitals are actively looking for to reduce their greenhouse gas emissions, and this study shows how recycling can help health centers cutting their CO2 emissions
Download the reportCarbon footprint evaluation of PVP (povidone), a key excipient for medicines
This study assessed the carbon footprint of 8 producers of polyvinylpyrrolidone (PVP) and analyzed key differences between regions
Download the reportCarbon footprint evaluation
of Metformin, depending on
production country
This study assessed the carbon footprint of 7 producers of Metformin, in Europe, India and China.
Download the reportCarbon footprint study on nitrile gloves, depending on production country
Ecovamed is starting to publish a series of carbon footprint evaluation of Health Products, comparing various production location.
Download the report
Ecovamed has been awarded
by BPI France
This award, with a financial contribution thanks to the "Bourse French Tech", will support the development of our technology
LinkedIn newsCarbon footprint evaluation of Ibuprofen, depending
on industrial process & country
This study assessed the carbon footprint of all producers of Ibuprofen around the world. Feel free to contact us if you need a similar study on other APIs
Download the reportEcovamed joins the ChemTech,
the netwok of innovative start'up
The ChemTech is a joint initiative of France Chimie and Bpifrance, to support start-up developing "chemical-oriented" solutions
ChemTech websiteCarbon footprint evaluation
of Active Pharmaceutical Ingredients
Publication of the first carbon footprint of Ibuprofen, thanks to newmethodology developed by Ecovamed.
Download the reportChimie Paris Innov welcome Ecovamed
in its incubator
This new location is a great opportunity for Ecovamed to keep innovating within the University Paris Sciences et Lettres (PSL) environment
Chimie Paris Innov website
Ecovamed attended the
G5 Santé event in October
The 10th "G5 Santé" meeting held in Paris gave the opportunity to all stakeholders to debate on health innovation and sovereignty
Any questions? Contact us!
*required fields
© 2021 Ecovamed. All rights reserved
